These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

250 related items for PubMed ID: 25965947

  • 1. Expression of the Carboxy-Terminal Portion of MUC16/CA125 Induces Transformation and Tumor Invasion.
    Rao TD, Tian H, Ma X, Yan X, Thapi S, Schultz N, Rosales N, Monette S, Wang A, Hyman DM, Levine DA, Solit D, Spriggs DR.
    PLoS One; 2015; 10(5):e0126633. PubMed ID: 25965947
    [Abstract] [Full Text] [Related]

  • 2. Transformation of NIH3T3 mouse fibroblast cells by MUC16 mucin (CA125) is driven by its cytoplasmic tail.
    Giannakouros P, Matte I, Rancourt C, Piché A.
    Int J Oncol; 2015 Jan; 46(1):91-8. PubMed ID: 25338620
    [Abstract] [Full Text] [Related]

  • 3. Ascites from ovarian cancer patients stimulates MUC16 mucin expression and secretion in human peritoneal mesothelial cells through an Akt-dependent pathway.
    Matte I, Garde-Granger P, Bessette P, Piché A.
    BMC Cancer; 2019 Apr 30; 19(1):406. PubMed ID: 31039761
    [Abstract] [Full Text] [Related]

  • 4. MUC16 (CA125) regulates epithelial ovarian cancer cell growth, tumorigenesis and metastasis.
    Thériault C, Pinard M, Comamala M, Migneault M, Beaudin J, Matte I, Boivin M, Piché A, Rancourt C.
    Gynecol Oncol; 2011 Jun 01; 121(3):434-43. PubMed ID: 21421261
    [Abstract] [Full Text] [Related]

  • 5. Development and characterization of carboxy-terminus specific monoclonal antibodies for understanding MUC16 cleavage in human ovarian cancer.
    Aithal A, Junker WM, Kshirsagar P, Das S, Kaur S, Orzechowski C, Gautam SK, Jahan R, Sheinin YM, Lakshmanan I, Ponnusamy MP, Batra SK, Jain M.
    PLoS One; 2018 Jun 01; 13(4):e0193907. PubMed ID: 29708979
    [Abstract] [Full Text] [Related]

  • 6. Antibodies Against Specific MUC16 Glycosylation Sites Inhibit Ovarian Cancer Growth.
    Rao TD, Fernández-Tejada A, Axelrod A, Rosales N, Yan X, Thapi S, Wang A, Park KJ, Nemieboka B, Xiang J, Lewis JS, Olvera N, Levine DA, Danishefsky SJ, Spriggs DR.
    ACS Chem Biol; 2017 Aug 18; 12(8):2085-2096. PubMed ID: 28617578
    [Abstract] [Full Text] [Related]

  • 7. The evolving role of MUC16 (CA125) in the transformation of ovarian cells and the progression of neoplasia.
    Giamougiannis P, Martin-Hirsch PL, Martin FL.
    Carcinogenesis; 2021 Apr 17; 42(3):327-343. PubMed ID: 33608706
    [Abstract] [Full Text] [Related]

  • 8. Transcriptional control of the MUC16 promoter facilitates follicle-stimulating hormone peptide-conjugated shRNA nanoparticle-mediated inhibition of ovarian carcinoma in vivo.
    Zhang MX, Hong SS, Cai QQ, Zhang M, Chen J, Zhang XY, Xu CJ.
    Drug Deliv; 2018 Nov 17; 25(1):797-806. PubMed ID: 29542355
    [Abstract] [Full Text] [Related]

  • 9. Downregulation of cell surface CA125/MUC16 induces epithelial-to-mesenchymal transition and restores EGFR signalling in NIH:OVCAR3 ovarian carcinoma cells.
    Comamala M, Pinard M, Thériault C, Matte I, Albert A, Boivin M, Beaudin J, Piché A, Rancourt C.
    Br J Cancer; 2011 Mar 15; 104(6):989-99. PubMed ID: 21326240
    [Abstract] [Full Text] [Related]

  • 10. Oncogenic KRAS Targets MUC16/CA125 in Pancreatic Ductal Adenocarcinoma.
    Liang C, Qin Y, Zhang B, Ji S, Shi S, Xu W, Liu J, Xiang J, Liang D, Hu Q, Ni Q, Xu J, Yu X.
    Mol Cancer Res; 2017 Feb 15; 15(2):201-212. PubMed ID: 28108627
    [Abstract] [Full Text] [Related]

  • 11. Membrane-type I matrix metalloproteinase-dependent ectodomain shedding of mucin16/ CA-125 on ovarian cancer cells modulates adhesion and invasion of peritoneal mesothelium.
    Bruney L, Conley KC, Moss NM, Liu Y, Stack MS.
    Biol Chem; 2014 Oct 15; 395(10):1221-31. PubMed ID: 25205731
    [Abstract] [Full Text] [Related]

  • 12. MUC16 expression during embryogenesis, in adult tissues, and ovarian cancer in the mouse.
    Wang Y, Cheon DJ, Lu Z, Cunningham SL, Chen CM, Luo RZ, Xing D, Orsulic S, Bast RC, Behringer RR.
    Differentiation; 2008 Dec 15; 76(10):1081-92. PubMed ID: 18637025
    [Abstract] [Full Text] [Related]

  • 13. MUC16 mucin (CA125) attenuates TRAIL-induced apoptosis by decreasing TRAIL receptor R2 expression and increasing c-FLIP expression.
    Matte I, Lane D, Boivin M, Rancourt C, Piché A.
    BMC Cancer; 2014 Apr 01; 14():234. PubMed ID: 24690311
    [Abstract] [Full Text] [Related]

  • 14. Radiopharmacologic screening of antibodies to the unshed ectodomain of MUC16 in ovarian cancer identifies a lead candidate for clinical translation.
    Nemieboka B, Sharma SK, Rao TD, Edwards KJ, Yan S, Wang P, Ragupathi A, Piersigilli A, Spriggs DR, Lewis JS.
    Nucl Med Biol; 2020 Apr 01; 86-87():9-19. PubMed ID: 32403071
    [Abstract] [Full Text] [Related]

  • 15. Novel monoclonal antibodies against the proximal (carboxy-terminal) portions of MUC16.
    Dharma Rao T, Park KJ, Smith-Jones P, Iasonos A, Linkov I, Soslow RA, Spriggs DR.
    Appl Immunohistochem Mol Morphol; 2010 Oct 01; 18(5):462-72. PubMed ID: 20453816
    [Abstract] [Full Text] [Related]

  • 16. CA125 (MUC16) gene silencing suppresses growth properties of ovarian and breast cancer cells.
    Reinartz S, Failer S, Schuell T, Wagner U.
    Eur J Cancer; 2012 Jul 01; 48(10):1558-69. PubMed ID: 21852110
    [Abstract] [Full Text] [Related]

  • 17. CA125 (MUC16) tumor antigen selectively modulates the sensitivity of ovarian cancer cells to genotoxic drug-induced apoptosis.
    Boivin M, Lane D, Piché A, Rancourt C.
    Gynecol Oncol; 2009 Dec 01; 115(3):407-13. PubMed ID: 19747716
    [Abstract] [Full Text] [Related]

  • 18. Ovarian cancer antigen CA125 is encoded by the MUC16 mucin gene.
    Yin BW, Dnistrian A, Lloyd KO.
    Int J Cancer; 2002 Apr 10; 98(5):737-40. PubMed ID: 11920644
    [Abstract] [Full Text] [Related]

  • 19. Virus-like particle vaccine displaying an external, membrane adjacent MUC16 epitope elicits ovarian cancer-reactive antibodies.
    Tu HF, Wong M, Tseng SH, Ingavat N, Olczak P, Notarte KI, Hung CF, Roden RBS.
    J Ovarian Res; 2024 Jan 16; 17(1):19. PubMed ID: 38225646
    [Abstract] [Full Text] [Related]

  • 20. Dual-fluorescence isogenic high-content screening for MUC16/CA125 selective agents.
    Rao TD, Rosales N, Spriggs DR.
    Mol Cancer Ther; 2011 Oct 16; 10(10):1939-48. PubMed ID: 21817115
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.